As of 07 March 2023, the Health Technology Assessment Council (HTA Council) has completed the assessment and deliberation for the preliminary recommendation on dapagliflozin 10 mg single-dose film-coated tablets as add-on treatment for adults with Type 2 Diabetes Mellitus including those who have or are at high risk of cardiovascular disease and/or diabetic neuropathy. The continue reading : [Announcement] HTA Council Releases Its Preliminary Recommendation on the Financing of Dapagliflozin for Patients with Type 2 Diabetes Mellitus